IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Clearstead Trust LLC

Clearstead Trust LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 25.0% in the second quarter, Holdings Channel.com reports. The institutional investor owned 360 shares of the medical research company’s stock after purchasing an additional 72 shares during the quarter. Clearstead Trust LLC’s holdings in IQVIA were worth $76,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Versant Capital Management Inc grew its stake in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of IQVIA in the second quarter valued at about $27,000. Rise Advisors LLC acquired a new stake in shares of IQVIA in the first quarter valued at about $31,000. Riverview Trust Co acquired a new stake in shares of IQVIA in the first quarter valued at about $32,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the second quarter valued at about $32,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 0.3 %

NYSE:IQV opened at $239.38 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The business’s 50 day moving average is $238.59 and its two-hundred day moving average is $234.21. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a market cap of $43.64 billion, a PE ratio of 32.70, a P/E/G ratio of 2.24 and a beta of 1.49.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business posted $2.22 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on IQV shares. The Goldman Sachs Group started coverage on IQVIA in a research note on Thursday, June 6th. They issued a “buy” rating and a $270.00 target price for the company. Truist Financial raised their price objective on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Barclays raised their price objective on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. UBS Group raised their price objective on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, Royal Bank of Canada started coverage on IQVIA in a research note on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $266.67.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.